Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00277758 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00277758 is a Phase 1 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 18 participants.
The verdict
NCT00277758, a Phase 1 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a treatment study trial, in which we will assess the safety and tolerability of daily dose IL-2, as monotherapy for 12 weeks, followed by IL2 in combination with PEG-IFN and RBV for 48 weeks in the treatment of chronic Hepatitis C.
Interventions
- DRUG Ribavirin
- BIOLOGICAL Interleukin 2
- BIOLOGICAL Pegylated Interferon Alpha
- BIOLOGICAL Inteleukin-2
- DRUG Ribavirin + Pegylated interferon-alpha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2004-03 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00277758
The ClinicalTrials.gov registry entry for NCT00277758 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ribavirin is the first listed.
NCT00277758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00277758 about?
NCT00277758 is a clinical study titled "Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I". This is a treatment study trial, in which we will assess the safety and tolerability of daily dose IL-2, as monotherapy for 12 weeks, followed by IL2 in combination with PEG-IFN and RBV for 48 weeks in the treatment of chronic Hepatitis C.
What is the current status of trial NCT00277758?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2004-03. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00277758?
The interventions under investigation include: Ribavirin (DRUG), Interleukin 2 (BIOLOGICAL), Pegylated Interferon Alpha (BIOLOGICAL), Inteleukin-2 (BIOLOGICAL), Ribavirin + Pegylated interferon-alpha (DRUG).
Who is sponsoring clinical trial NCT00277758?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.